bamlanivimab
mAbexperimentalCOVID-19
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
1
Earliest trial started Feb 12, 2021 (NCT04748588)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Studied for
Mechanism of action
- Spike glycoproteinANTAGONIST
Spike glycoprotein antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05205759 | Phase 3 | Dec 9, 2021 | Agenzia Italiana del Farmaco, University of Udine, University of Verona |
| NCT04748588 | Phase 4 | Feb 12, 2021 | University of British Columbia, University of Calgary, University of Toronto |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Agenzia Italiana del Farmaco | Government | 1 | 0 | 1 | 2021 |
| University of British Columbia | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Calgary | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Udine | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Verona | Academic/Hospital | 1 | 1 | 1 | 2021 |
6 organizations
Page 1 / 1